M. Nakamura

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

H. Utsumi, S. Kiuchi, Yoshinobu Nakamaru, 2012, Bioorganic & medicinal chemistry.

Identification of a Potent and Orally Active Non-peptide C5a Receptor Antagonist*

H. Sumichika, K. Sakata, N. Sato, 2002, The Journal of Biological Chemistry.

Removal of sphingosine 1-phosphate receptor-3 (S1P(3)) agonism is essential, but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P(1) agonists with reduced effect on heart rate.

K. Adachi, K. Sugahara, Mahoko Asayama, 2010, Journal of medicinal chemistry.

Synthesis and Synthetic Application of Phosphonoketene Dithioacetals. New Synthesis of Dithioallenes and (alpha-Dithiocarboxyvinyl)phosphonates.

T. Okauchi, T. Minami, J. Ichikawa, 1996, The Journal of organic chemistry.

Synthesis and Synthetic Utilization of alpha-Functionalized Vinylphosphonates Bearing beta-Oxy or beta-Thio Substituents.

T. Okauchi, T. Minami, J. Ichikawa, 1998, The Journal of organic chemistry.

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

H. Utsumi, S. Kiuchi, Yoshinobu Nakamaru, 2012, Bioorganic & medicinal chemistry.

1-((S)-gamma-substituted prolyl)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP-IV inhibitors.

H. Sakashita, H. Kitajima, F. Akahoshi, 2005, Bioorganic & medicinal chemistry letters.